Pulmonary Hypertension News – Pulmonary Hypertension News
2024年12月16日 · CS1 expanded access program for PAH now covers 10 patients. Cereno Scientific said it has enrolled nine additional people with pulmonary arterial hypertension (PAH) in its expanded access program (EAP) for investigational therapy CS1, bringing the total number of patients in the program to 10.
Non-oral PAH treatment adds challenges for patients: Study
2024年1月6日 · The study, “Patients’ perspectives on the challenges associated with receiving non-oral pulmonary arterial hypertension treatment: a mixed methods study,” was published in Therapeutic Advances in Respiratory Disease. PAH is high blood pressure in the blood vessels that supply the lungs. It occurs when small blood vessels narrow and blood can’t flow through as well as it should.
Pulmonary Arterial Pressure Above 30 mmHg Linked to Increased...
2019年7月8日 · An estimated right ventricular systolic pressure (eRVSP) — a measure of the pressure inside the artery that supplies blood to the lungs (pulmonary artery) — greater than 30.0 mmHg is related to an increased risk of mortality in patients with pulmonary hypertension (PH), according to a new Australian study.
Top 10 Pulmonary Hypertension Stories of 2022 | Key Topics:...
2022年12月29日 · Opsumit (macitentan) is a daily oral therapy that’s approved to treat pulmonary arterial hypertension (PAH). In this study, researchers analyzed data from the Phase 3 clinical trial SERAPHIN (NCT00660179) and its open-label extension (NCT00667823) to evaluate the therapy’s long-term effect on survival.Nearly three-quarters (73.3%) of patients were alive at five years, and more than half ...
Approval of new treatments for pulmonary hypertension prompts...
2024年4月3日 · First, in late March, the FDA approved a once-daily, fixed-dose tablet containing a combination of macitentan and tadalafil for adults with pulmonary arterial hypertension (PAH). It will be marketed under the brand name Opsynvi and is the first single-tablet treatment combination to become available to people with PAH in the U.S.. Then, just days later, the FDA approved the under-the-skin ...
Top 10 Pulmonary Hypertension Stories of 2021 – Pulmonary...
2022年1月3日 · The U.S. Food and Drug Administration (FDA), however, declined to approve Tyvaso DPI in October due to an inspection issue at a third-party manufacturing facility. United Therapeutics announced an intention to address this single issue. No. 6 – “Uptravi Found to Reduce Risk, by Half, of PAH Disease Progression“ The Phase 3 clinical trials GRIPHON (NCT01106014) and TRITON (NCT02558231 ...
Breathing problems while sleeping linked to worsening PAH: Study
2023年12月4日 · People with pulmonary arterial hypertension (PAH) who have problems breathing while they’re sleeping — causing nocturnal hypoxemia, or oxygen levels in the blood to drop during the night — are nearly twice as likely as patients without such difficulty to experience clinical worsening, a study found.
Pulmonary hypertension death rate falling, but not all across globe
2024年3月6日 · While all types of PH are linked to an increased risk of death, there are limited data on mortality trends around the world. To get a broader picture of PH-related mortality trends, the researchers drew on World Health Organization data. Between 2000 and 2019, PH accounted for 491,287 deaths across the 54 countries included in the report.
Pulmonary Hypertension Overview
2021年7月6日 · Group 2 includes PH caused by left heart disease. This is the most common type and includes pulmonary venous hypertension, which is when the heart is not able to efficiently carry blood away from the lungs.. Group 3 is PH due to lung diseases and/or hypoxia, which means low oxygen levels.
Top 10 Pulmonary Hypertension Stories of 2020
2021年1月4日 · As we anticipate bringing you more PH news this year, we take a look back at our top 10 most-read stories of 2020, with a summary of their significance for the PH community. No. 10 — “PAH Orenitram Drug More Cost-effective Than Uptravi, Study Suggests” A study found that in people with pulmonary arterial hypertension (PAH), …